MAI Capital Management Has $8.63 Million Position in Becton, Dickinson and Company (NYSE:BDX)

MAI Capital Management decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 6.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,812 shares of the medical instruments supplier’s stock after selling 2,470 shares during the period. MAI Capital Management’s holdings in Becton, Dickinson and Company were worth $8,634,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. PineStone Asset Management Inc. boosted its position in shares of Becton, Dickinson and Company by 141.6% during the second quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock valued at $314,544,000 after buying an additional 788,735 shares during the last quarter. First Eagle Investment Management LLC grew its stake in shares of Becton, Dickinson and Company by 32.5% in the 2nd quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after acquiring an additional 688,296 shares in the last quarter. Vaughan Nelson Investment Management L.P. bought a new position in shares of Becton, Dickinson and Company during the third quarter valued at about $108,243,000. Bank of New York Mellon Corp boosted its holdings in Becton, Dickinson and Company by 8.5% during the second quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after purchasing an additional 346,720 shares during the last quarter. Finally, Magnetar Financial LLC purchased a new stake in Becton, Dickinson and Company in the 1st quarter valued at about $75,493,000. 86.97% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Evercore ISI raised their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Stifel Nicolaus lifted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Raymond James cut their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Becton, Dickinson and Company presently has an average rating of “Buy” and an average price target of $283.00.

Becton, Dickinson and Company Trading Down 0.4 %

Shares of Becton, Dickinson and Company stock opened at $224.14 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $249.89. The firm has a market cap of $64.79 billion, a PE ratio of 37.73, a PEG ratio of 1.68 and a beta of 0.43. The company has a 50 day simple moving average of $236.03 and a two-hundred day simple moving average of $234.89.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same period in the previous year, the business earned $3.42 earnings per share. The firm’s quarterly revenue was up 6.9% compared to the same quarter last year. Analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, December 9th. This represents a $4.16 annualized dividend and a yield of 1.86%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio is currently 63.97%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.